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deletion also includes the  RASA1 gene show features of the 
respective capillary and arterio-venous malformations and 
fistula syndrome. The phenotypic overlap with Rett syn-
drome is explained by a shared pathway and, accordingly, 
diminished  MECP2 and  CDKL5 expression is measureable in 
patients with  MEF2C defects. Further research of this path-
way may therefore eventually lead to a common therapeutic 
target. 
 
Copyright © 2012 S. Karger AG, Basel 
 History of the Syndrome 
 As a result of joint efforts of the German Mental Re-
tardation Network (MRNET) and the Decipher database, 
Engels, Firth and Rauch initiated a study on 5q14.3q15 
microdeletions and delineated a novel syndrome charac-
terized by severe psychomotor retardation, epilepsy or fe-
brile seizures, muscular hypotonia and variable brain 
and minor anomalies [Engels et al., 2009]. These dele-
tions partially overlapped with the distally more extend-
ed deletions in 3 patients with severe mental retardation, 
seizures and periventricular heterotopia described by 
Cardoso et al. [2009]. The 1.6-Mb smallest region of over-
lap contained the neurodevelopmental  LYSMD3 gene as 
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 Abstract 
 Disorders related to the autosomal transcription factor 
 MEF2C located in 5q14.3 were first described in 2009 and 
have since evolved to one of the more common microdele-
tion syndromes. Mutational screening in a larger cohort re-
vealed heterozygous de novo mutations of  MEF2C in about 
1% of patients with moderate to severe intellectual disability, 
and the phenotype is similar in patients with intragenic dele-
tions and multigenic microdeletions. Clinically,  MEF2C -relat-
ed disorders are characterized by severe intellectual disabil-
ity with absent speech and limited walking abilities, hypo-
tonia, seizures, and a variety of minor brain anomalies. The 
majority of patients show a similar facial gestalt with broad 
forehead, flat nasal bridge, hypotonic mouth, and small chin, 
as well as strabismus, but this phenotype is clinically not well 
recognized. The course of the disease is generally quite uni-
form, but patients with point mutations and smaller dele-
tions seem to have a higher chance of walking skills and a 
lower risk of refractory seizures. Patients in whom the micro-
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a potential underlying cause of intellectual disability and 
the  GPR98/MASS1 gene was considered potentially re-
lated to seizures [Engels et al., 2009]. However, the obser-
vation of 2 very similar patients with more proximal dele-
tions not overlapping the 1.6-Mb smallest region of over-
lap led Zweier et al. [2010] to further investigate the 
nearby  MEF2C gene as a potential monogenic cause of 
the 5q14.3q15 microdeletion syndrome ( fig.  1 ). They 
showed that  MEF2C expression levels were indeed sig-
nificantly decreased in blood probes of their novel pa-
tients as well as in all patients described by Engels et al. 
[2009], indicating  MEF2C as the underlying gene and a 
positional effect in the patient with a deletion breakpoint 
distal to  MEF2C . Accordingly, subsequent mutational 
screening in patients with moderate to severe intellectual 
disability of unknown cause revealed 4  MEF2C de novo 
mutations in patients with similar phenotype as seen in 
patients with larger deletions [Zweier et al., 2010]. At the 
same time Le Meur et al. [2010] independently identified 
 MEF2C as the gene underlying the 5q14.3q15 microdele-
tion syndrome by detection of a microdeletion limited to 
 MEF2C only and subsequent identification of a  MEF2C 
stop mutation in a similar patient. Both Zweier et al. 
[2010] and Le Meur et al. [2010] pointed out the pheno-
typic overlap to Rett syndrome, and Zweier et al. [2010] 
demonstrated molecular interaction of the respective 
genes. Attributable to the wide use of molecular karyo-
typing or array comparative genomic hybridization, by 
now a total of 23 patients with 5q14.3q15 microdeletions 
have been reported [Cardoso et al., 2009; Engels et al., 
2009; Berland and Houge, 2010; Le Meur et al., 2010; No-
vara et al., 2010; Nowakowska et al., 2010; Zweier et al., 
2010; Carr et al., 2011; Mikhail et al., 2011; Tonk et al., 
2011], but no further patients with point mutations, indi-
cating that the phenotype is not well recognized. Sixteen 
microdeletions involved  MEF2C and additional genes, 3 
multi-gene microdeletions had a proximal breakpoint 
close to, but distally to  MEF2C  [Cardoso et al., 2009; En-
gels et al., 2009], and 4 microdeletions involved  MEF2C 
only [Le Meur et al., 2010; Novara et al., 2010; Nowakow-
ska et al., 2010; Mikhail et al., 2011]. Of note, one of the 
balanced translocation breakpoints in a patient with se-
vere intellectual disability, early-onset epileptic encepha-
lopathy, and hypoplastic corpus callosum was mapped 
121.5 kb upstream of  MEF2C [Saitsu et al., 2011].
 Clinical Features 
 Neurodevelopmental Signs 
 Apart from 1 exceptional patient, all patients with mu-
tations or microdeletions uniformly showed severe men-
tal retardation with absent speech, limited walking abili-
ties and lack of gross malformations ( table 1 ). The excep-
tional patient described by Tonk et al. [2011] with the 
largest deletion of 21 Mb only had mild intellectual dis-
ability with a global IQ of 69 and a seizure disorder. It was 
hypothesized that the large extent of the deletion could 
have a compensatory effect explaining the mild pheno-
type. However, hidden mosaicism may be a more likely 
explanation since overlapping cytogenetically visible de-
letions were associated with significant dysmorphism 
and mental disability. Seven of 9 patients with  MEF2C 
limited mutations or deletions, 17 of 19 with larger dele-
tions, and overall all patients older than 3 years had sei-
zures. However, the age of onset was usually in infancy or 
early childhood and commonly associated with fever. 
The majority of patients had tonic-clonic seizures, but 
myoclonic or complex partial seizures as well as infantile 
spasms were also described. Seizures were well controlled 
in the majority of patients, but were refractory in 3 pa-
tients with deletions exceeding the  MEF2C gene [Le Meur 
 Fig. 1. Partial scheme of the gene content of the 15q14.3q15 microdeletion region with the first smallest region 
of overlap (SRO1) defined by 6 cases reported by Engels et al. [2009] and Cardoso et al. [2009], and the distinct 
SRO2 delineated by Zweier et al. [2010] through 2 novel cases. 
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et al., 2010; Novara et al., 2010]. Mild to severe hypotonia 
was reported in 17 of 19 patients with larger deletions and 
in 6 of 9 patients with  MEF2C defects. The ability to walk 
independently was reported only in the following few pa-
tients: at the age of 2 years 8 months in a boy with p.E34X 
mutation [Zweier et al., 2010], at the age of 3 years in a girl 
with p.S228X mutation [Le Meur et al., 2010], at the ages 
of 5 and 3 years, respectively, in 2 patients with larger de-
letions distally to  MEF2C [Cardoso et al., 2009], and at 
the age of 11 years in a girl with a 1.15-Mb deletion in-
cluding  MEF2C and  TMEM161B [Berland and Houge, 
2010]. Developmental milestones of the exceptionally 
mildly affected patient with the 21-Mb deletion were 
within the normal range [Tonk et al., 2011]. Stereotypic 
movements including bruxism, head rocking, hand 
washing or clapping, hand-mouth movements, and oth-
ers, as well as autistic features or poor eye contact were 
reported in nearly half of the patients (13 of 28 each). Ep-
isodic hyperventilation and apnea was reported in 2 pa-
tients with  MEF2C limited defects only [Le Meur et al., 
2010; Zweier et al., 2010].
 MRI was reported to show minor anomalies in 24 pa-
tients without any consistent pattern. Observed anoma-
lies included delayed myelinization, enlarged ventricles, 
hypoplastic or thickened corpus callosum, periventricu-
lar heterotopia, simplified gyral pattern, polymicrogyria, 
colpocephaly, and periventricular leucomalacia.
 Growth Parameters and Other Features 
 Height, weight and head circumference are common-
ly within the normal range, but are abnormal in both di-
rections in some patients. While some patients showed 
relative or absolute macrocephaly, others had relative or 
absolute microcephaly. Although most patients show a 
variety of minor anomalies, no easily recognizable facial 
phenotype evolved. However, broad and/or high, bulging 
forehead, upslanting palpebral fissures, flat nasal root 
and bridge, small, upturned nose, hypotonic small mouth, 
large ears with prominent lobes, and small chin, as well 
as strabismus are the most consistent facial features re-
ported. Unique, special anomalies were substernal fistu-
la, jugular pit, bilateral club feet, and postaxial polydac-
tyly of toes, all observed in deletions involving more than 
the  MEF2C gene. While few patients had hypermetropia 
or myopia, hearing loss was not reported.
 As pointed out by Carr et al. [2011] in patients with 
deletions including the  RASA1 gene located proximally 
to  MEF2C , capillary or arterio-venous malformations or 
fistulae (CMs, AVMs, AVFs) should be expected. The 
 RASA1 associated autosomal dominant CM-AVM-syn-
drome is characterized by multiple pink-red, round, or 
oval CMs mostly localized on the face and limbs increas-
ing in number with age ( fig. 2 ) [Carr et al., 2011]. About 
30% of affected individuals have associated AVMs and/or 
AVFs which are typically located in the head and neck 
region [Bayrak-Toydemir and Stevenson, 1993–2011; 
Boon et al., 2005]. These fast-flow vascular anomalies 
typically arise in the skin, muscle, bone, spine, and brain, 
and life-threatening complications may include bleeding, 
congestive heart failure, or neurologic symptoms which 
seem to occur early in life [Bayrak-Toydemir and Steven-
son, 1993–2011]. Some patients have the clinical diagnosis 
of Parkes Weber syndrome (multiple micro-AVFs associ-
ated with a cutaneous capillary stain and excessive soft 
Table 1. Features frequently observed in patients with MEF2C defects and 5q14.3q15 microdeletions
Features 5q14.3q15 multigenic microdeletionsa
(n = 19)
MEF2C limited defects
(n = 9)
All together
(n = 28)
Severe intellectual disability with absent speech 18 (95%) 9 (100%) 27 (96%)
MRI anomalies 17 (89%) 7 (77%) 24 (86%)
Seizures 17 (89%) 7 (77%) 24 (86%)
Hypotonia 17 (89%) 6 (66%) 23 (85%)
Repetitive movements 9 (47%) 4 (44%) 13 (46%)
Autistic features or poor eye contact 8 (42%) 4 (44%) 12 (43%)
Strabism 6 (32%) 3 (33%) 9 (32%)
Episodic hyperventilation 0 2 (22%) 2 (7%)
Broad/high or bulging forehead 13 (68%) 6 (66%) 19 (68%)
a Two of these deletions described by Cardoso et al. [2009] do not involve  MEF2C and it was not proven if they have a positional 
effect on  MEF2C .
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tissue and skeletal growth of an affected limb) [Bayrak-
Toydemir and Stevenson, 1993–2011].
 Natural History and Disease Management 
 So far there is no evidence for specific internal or life-
threatening complications associated with  MEF2C de-
fects. However, the oldest age of investigation in reported 
patients was 18 years only. Seizures seem to be benign or 
well controllable by standard treatment such as valproate 
in the majority of patients. For AVMs or AVFs, the indi-
vidual risks and benefits of intervention have to be con-
sidered.
 Genetics 
 MEF2C Gene and Protein Function 
 The  MEF2C  gene, first identified by Leifer et al. [1993], 
is located within the microdeletion syndrome region on 
chromosome 5q14.3. Three transcriptional start sites 
with variable 5  -untranslated regions are annotated and 
 MEF2C contains up to 11 coding exons spanning ap-
proximately 100 kb of genomic DNA ( fig. 3 ). Up to now, 
6 transcript variants in humans are annotated (Ref
Seq: NM_002397, NM_001131005, NM_001193347, 
NM_001193348, NM_001193349, NM_001193350). The 
longest of these variants encodes for a 483-amino-acid 
protein, the shortest one for 393 amino acids.
 Like all members of the MADS family (MCM1-aga-
mous-deficiens-serum response factor) MEF2C, which 
belongs to the myocyte enhancer factor 2 (MEF2) sub-
family, is characterized by a highly conserved N-terminal 
MADS box. Together with the directly adjacent subfam-
ily-specific MEF2 domain motif it mediates dimeriza-
tion, DNA binding, and cofactor interaction [Potthoff 
and Olson, 2007]. It is also known that MEF2 family 
members possess strong nuclear localization signals, for 
MEF2C it is reported in the N-terminal region [Janson et 
al., 2001]. The C-terminal region of MEF2 proteins con-
tains the transcriptional activation domains, differs be-
tween family members, and is subject to complex pat-
terns of alternative splicing ( fig. 3 ). Whereas vertebrates 
have 4  MEF2 genes,  MEF2A–D , yeast,  Drosophila , and 
 Caenorhabditis elegans possess only a single  Mef2 gene. 
MEF2 factors bind to the A/T rich consensus DNA 
 sequence YTA(A/T) 4 TAR as homo- and heterodimers. 
Their transcriptional activity relies on the recruitment of 
and cooperation with many other transcription factors, 
as well as on translational and posttranslational modifi-
cations [Potthoff and Olson, 2007]. For instance, phos-
phorylation of a highly conserved site enhances the DNA 
binding activity of MEF2C [Molkentin et al., 1996]. MEF2 
proteins are known to act as central regulators of diverse 
developmental programs [Potthoff and Olson, 2007]. The 
4 vertebrate  MEF2 genes display overlapping, but distinct 
temporal and spatial expression patterns during embry-
onic development and in adult tissues with highest ex-
pression in striated muscles and brain [Edmondson et al., 
1994].
 Regarding  MEF2C in particular, high expression lev-
els were detected in skeletal muscle, cardiac muscle and 
brain in both humans and mice [Edmondson et al., 1994; 
Zweier et al., 2010]. It is reported to be highly expressed 
in the embryonic cerebral cortex, hippocampus, amyg-
dala, midbrain, olfactory bulb, and cerebellum, as well as 
in the adult frontal cortex, dentate gyrus, hippocampus, 
thalamus, and cerebellum in the development of mouse 
CNS [Lyons et al., 1995]. Alternatively spliced MEF2C 
transcripts differ significantly in both expression pattern 
and transactivation functions, some of them shown to be 
brain-specific [Leifer et al., 1993; Janson et al., 2001; Zwei-
er et al., 2010].
 Fig. 2. Clinical photographs of a previously unpublished patient 
with 15q14.3q15 microdeletion amongst others including the 
 MEF2C and  RASA1 genes, at the age of 14 months. Note the typi-
cal facial features with high, broad and bulging forehead, upslant-
ing palpebral fissures, flat nasal root and bridge, small nose with 
anteverted nares, small mouth with downturned corners, mild 
retrognathia, large ears with up-lifted, prominent earlobes, as 
well as multiple round CMs of variable size. 
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 Previous studies revealed an important role of  Mef2c 
in several differentiation and developmental processes 
like myogenesis, the development of the anterior heart 
field, neural crest and craniofacial development, chon-
drocyte hypertrophy and vascularization, endothelial 
cell proliferation and survival, lymphoid development, 
neurogenesis, and synaptic formation [Potthoff and Ol-
son, 2007; Li et al., 2008a, b; Stehling-Sun et al., 2009]. 
 Mef2c homozygous knockout in mice results in embry-
onic lethality due to cardiovascular defects even before 
brain development [Lin et al., 1997], resembling the indi-
cated crucial role of MEF2C in developmental processes. 
However, in vivo analysis of the neuronal function of 
MEF2C using a conditional homozygous deletion of mu-
rine  Mef2c in radial glial cells during late embryogenesis 
and expression of a superactive form of  Mef2c in neurons 
indicated an essential role in hippocampus-dependent 
learning and memory by suppressing the number of ex-
citatory synapses and thus regulating basal and evoked 
synaptic transmission [Barbosa et al., 2008]. Interesting-
ly, Li et al. [2008a] reported that mice with conditional 
 Mef2c knockout in neural progenitors have abnormal ag-
gregation and compaction of neurons migrating into the 
lower layers of the neocortex during development. This 
manifested in smaller brain size with smaller, less mature 
neurons in adulthood, with resultant aberrant electro-
physiology and severe behavioral anomalies resembling 
those seen in mouse models of Rett syndrome-like altered 
anxiety and paw-clasping [Li et al., 2008a]. Supported by 
a study showing that activated MEF2C drives the forma-
tion of neurons from murine stem cells [Li et al., 2008b], 
this work indicates the pivotal role of MEF2C in early 
neuronal differentiation and offers a phenotypic link to 
Rett syndrome.
 The phenotype of murine models of  Mef2c inactivation 
and the biological function in neuronal pathways sup-
b
a
 Fig. 3. Genomic and protein structure of MEF2C and the respec-
tive location of all point mutations published so far.  a Schematic 
representation of the  MEF2C gene. The 3 annotated transcription 
start sites are shown as dashed arrows, the non-coding exons for 
the untranslated region are depicted as white boxes, and the start 
codon as a black arrow. The universal coding exons are shown as 
grey boxes, black-marked regions are coding for the MADS do-
main, dark grey regions for the MEF2 domain, and sequences 
coding for alternatively spliced elements   1,   2,   and   are rep-
resented by differently dashed boxes.  b Schematic representation 
of the protein structure of MEF2C and its alternatively spliced 
transcripts. MADS and MEF2 domains are required for DNA 
binding and dimerization, while the transactivation domains are 
required for transcriptional activation via protein-protein inter-
actions. Alternative splicing occurs in the region immediately ad-
jacent to the MEF2 domain (  1,   2; unclear function), in the 
transactivation region (  ; inclusion is brain specific) [Leifer et al., 
1993; Janson et al., 2001; Zweier et al., 2010] and within the last 
coding exons (  ; suggested transcriptional repression domain) 
[Janson et al., 2001]. 
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ports the causal role of defects in  MEF2C for the severe 
mental retardation phenotype observed in human pa-
tients with  MEF2C haploinsufficiency. Of note, in the hu-
man phenotype the impairment seems to be restricted to 
its central nervous functions [Le Meur et al., 2010; Zweier 
et al., 2010]. Trying to explain the observed phenotypic 
overlap of patients with  MEF2C mutations and atypical 
Rett syndrome and Pitt-Hopkins syndrome due to the in-
volvement of a common pathway, Zweier et al. [2010] 
found diminished  MECP2 and  CDKL5 expression in vivo 
in blood of  MEF2C -deficient patients. Supporting evi-
dence was given by transcriptional reporter assays indi-
cating that  MEF2C truncating and missense mutations 
diminish synergistic transactivation of E-box promoters 
including that of  MECP2 and  CDKL5 . These results are in 
line with other molecular findings indicating involve-
ment of MECP2 and CDKL5 in a common pathway [Mari 
et al., 2005]. Of note, MECP2 binding to the murine  Mef2c 
promoter as a repressor was shown by [Chahrour et al., 
2008]. In contrast, consistently altered expression levels of 
 TCF4 , mutations which cause Pitt-Hopkins syndrome 
[Zweier et al., 2007], were not found in  MEF2C -deficient 
patients. Therefore, a molecular link between MEF2C and 
TCF4 at this level was not obvious [Zweier et al., 2010].
 MEF2 proteins like MEF2C are reported to cooperate 
with many different cofactors and promote gene expres-
sion of many different genes, some of which are respon-
sible for intellectual disability themselves. There is evi-
dence that fragile X mental retardation protein (FMRP) 
is required to enable MEF2 proteins to eliminate excit-
atory synapses in hippocampal neurons of mice [Pfeiffer 
et al., 2010].
 Expression profiling in hippocampal neurons of rats 
indicated that MEF2 proteins also regulate several tran-
scripts like Dia1, Pcdh10, and Ube3a in which defects are 
known to cause neurodevelopmental features such as 
 intellectual disability, epilepsy and autism [Flavell et al., 
2008; Morrow et al., 2008].
 Inheritance and Genotype-Phenotype Correlation 
 All reported  MEF2C mutations and microdeletions 
occurred de novo and have been heterozygous. Although 
no recurrence within siblings was observed so far, an ap-
proximately 1% recurrence risk is likely due to the pos-
sibility of parental germ line mosaicism. Similarity of the 
phenotype in microdeletions and point mutations indi-
cates haploinsufficiency as the underlying genetic mech-
anism. Moreover, Zweier et al. [2010] demonstrated sig-
nificantly diminished  MEF2C expression levels in pa-
tients with microdeletions and truncating mutations. In 
contrast,  MEF2C expression levels in patients with mis-
sense mutations were unaltered or significantly increased, 
but downstream effects on the expression levels of  MECP2 
and  CDKL5 was equally in patients with missense or 
truncating mutations and deletions. Both reported mis-
sense mutations are located in the MADS domain and 
like truncating mutations abolish the transcriptional ac-
tivity of MEF2C in vitro [Zweier et al., 2010].
 Despite the contiguous gene deletion phenotype asso-
ciated with the  RASA1 gene deletion, no striking geno-
type-phenotype correlation evolved so far. However, pa-
tients with point mutations and smaller deletions seem to 
have a higher chance of walking skills and a lower risk of 
refractory seizures.
 The only large scale mutational screening study iden-
tified  MEF2C mutations in 1.1% of patients with moder-
ate to severe intellectual disability of unknown cause and 
in about 2% of patients fitting into the spectrum of Rett 
syndrome-like disorders [Zweier et al., 2010]. Thus, 
 MEF2C-related disorders represent one of the more com-
mon causes of intellectual disability.
 Research towards Disease-Specific Therapeutic 
Approaches 
 So far no disease-specific therapeutic targets are 
known. However, due to the at least partially shared path-
way with typical and atypical Rett syndromes, further 
elucidation of this pathway may eventually lead to a com-
mon therapeutic approach in this group of disorders. 
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